Could less be more? new study tests stopping CLL drugs early for better outcomes

NCT ID NCT04722172

First seen Apr 11, 2026 · Last updated May 06, 2026 · Updated 3 times

Summary

This study tests whether people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) can safely stop treatment early if their cancer responds well. Instead of taking the drugs acalabrutinib and obinutuzumab continuously, participants who achieve deep remission will stop and be monitored. The goal is to reduce side effects and drug resistance while maintaining cancer control.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Hackensack Meridian Health (Data collection only)

    Hackensack, New Jersey, 07601, United States

  • Memorial Sloan Kettering Basking Ridge (All protocol activities)

    Basking Ridge, New Jersey, 07920, United States

  • Memorial Sloan Kettering Bergen (All protocol activities)

    Montvale, New Jersey, 07645, United States

  • Memorial Sloan Kettering Cancer Center (All Protocol Activities)

    New York, New York, 10065, United States

  • Memorial Sloan Kettering Commack (All protocol activities)

    Commack, New York, 11725, United States

  • Memorial Sloan Kettering Monmouth (All protocol activities)

    Middletown, New Jersey, 07748, United States

  • Memorial Sloan Kettering Nassau (All protocol activities)

    Uniondale, New York, 11553, United States

  • Memorial Sloan Kettering Westchester (All protocol activities)

    Harrison, New York, 10604, United States

Conditions

Explore the condition pages connected to this study.